Stem Cells

June 27, 2016
Will Mesoblast recover from Teva & Celgene setbacks?

Will Mesoblast recover from Teva & Celgene setbacks?

Australian Regenerative Medicine company Mesoblast recently suffered a significant financial setback in the ongoing development of MPC-150-IM, their experimental Phase III treatment for chronic heart failure, […]
May 18, 2016
Cell Therapy grants Japanese Licence for its Heart Regeneration Medicine to Daiichi Sankyo

Cell Therapy Ltd grants Japanese Licence for its Heart Regeneration Medicine to Daiichi Sankyo

Welsh stem cell company Cell Therapy Ltd. has granted Japanese drugmaker Daiichi Sankyo a license for Heartcel™, its promising cardiac regeneration medicine. Under the conditions of […]
Contact Us